# Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Source: https://onco.cc/trials/nct06780839/  
OnCo record `nct06780839` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ensartinib in lung cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.

## Summary

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD is a phase 2, interventional study registered as NCT06780839 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 70 participants, started 2025-01-15 and due to reach its primary completion in 2029-01-15. Interventions recorded: Ensartinib. Conditions listed: NSCLC, Stage I, II, IIIA, IIIB. Primary outcome: DFS. Lung eligibility wording from the registry: "Histologically confirmed primary non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06780839
- Phase: 2
- Setting: Postoperative Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: a Single-arm, Multicenter Study
- Sponsor: Peking University Cancer Hospital & Institute
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06780839: https://clinicaltrials.gov/study/NCT06780839

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Ensartinib](https://onco.cc/drugs/ensartinib/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06780839.json